Genetic Analysis
All subjects underwent genetic counseling. Before 2012, Sanger sequencing of all coding intron/exon boundaries of the following genes were available: MYBPC3, β-myosin heavy chain, cardiac troponin C, cardiac troponin T, cardiac troponin I, cardiac-regulatory myosin light chain, cardiac-essential myosin light chain, cardiac α-actin, α-tropomyosin, cysteineand glycine-rich protein 3, and titin-cap/telethonin. After the identification of a pathogenic mutation, genotyping was extended at the discretion of the treating physician. Since 2012, next-generation sequencing covering 48 genes is used. Because of this change in DNA analysis over time, subjects underwent either extensive genotyping (≥6 sarcomeric genes) or limited genotyping (MYBPC3 only). Extensive genotyping was performed in 77 (57%) FG+ probands with HCM, 57 (42%) G+ probands with HCM, and 244 (88%) G− probands with HCM. Next-generation sequencing was performed in 15 (11%) FG+ probands with HCM, 30 (22%) G+ probands with HCM, and 116 (60%) G− probands with HCM. Seven of 9 (78%) individuals with non-HCM phenotypes underwent extensive genotyping.
Relatives in FG+ families were tested for the familial mutation and referred for cardiac screening if the mutation was present. 11 Genetic testing before adulthood was offered in families with severe HCM in childhood, when cardiac symptoms were present, or severe anxiety among parents existed.
Cardiac Evaluation
All individuals underwent periodic cardiac evaluation, including history, clinical examination, electrocardiography, and echocardiography. Echocardiographic studies were analyzed according to the American Society of Echocardiography guidelines. 12 In probands, HCM was diagnosed when maximal wall thickness (MWT) ≥15 mm, a cutoff value of 13 mm was used in relatives. 13 DCM was diagnosed based on left ventricular (LV) dilatation and LV systolic dysfunction.
14 NCCM diagnosis was based on the Jenni criteria. 15 MWT, LV end-diastolic diameter, left atrial size, and LV outflow tract (LVOT) velocity at rest and during provocation were measured. LVOT gradient was calculated with the Bernoulli equation. Systolic LV function was assessed using the wall motion score index and described as normal, mildly reduced, moderately reduced, or poor, which corresponded with LV ejection fractions of ≥55%, 45% to 54%, 30% to 44%, and <30%, respectively, according to echocardiography guidelines. 16 Systolic dysfunction was defined as mildly reduced, moderately reduced, or poor systolic function. Diastolic LV function was described as normal, abnormal relaxation (stage I), pseudonormal (stage II), and restrictive filling (stage III). 17 Clinical disease stages were defined according to Olivotto et al 18 : (1) nonhypertrophic (MWT <13 mm), (2) classic phenotype (MWT ≥13 mm and normal systolic LV function), (3) adverse remodeling (mildly reduced systolic LV function), and (4) overt cardiac dysfunction (moderately reduced or poor systolic LV function). After cardiomyopathy diagnosis, cardiac evaluation was extended with exercise testing and 24-hour ambulatory electrocardiographic monitoring. Nonsustained ventricular tachycardia was defined as ≥3 consecutive beats at ≥120/min lasting <30 seconds.
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Patient Follow-Up
Follow-up data were obtained in January 2016. Follow-up was complete for 99% of patients. Patients who were lost to follow-up were censored at the time of last follow-up. Mortality was retrieved from the civil service register and cause of death from the medical chart or the general practitioner. Septal reduction therapy and implantable cardioverter defibrillator (ICD) were registered. ICDs were implanted according to the guidelines. 13, 19, 20 Cardiovascular mortality was defined as the combined end point of sudden cardiac death (SCD)/aborted SCD, heart failure (HF)-related death (including heart transplantation), stroke-related death, coronary artery disease-related death, and procedure-related cardiac death. SCD/aborted SCD was defined as (1) instantaneous and unexpected death in patients who were previously in a stable condition, or nocturnal death with no antecedent history of worsening symptoms; (2) resuscitation after cardiac arrest; or (3) appropriate ICD intervention for ventricular fibrillation or ventricular tachycardia >200 bpm.
Statistical Analysis
Calculations were performed using SPSS 21 (IBM, Armonk, New York) and R Statistical Software, version 3.2.4., using packages survival and lme4. Normally distributed continuous data are expressed as mean + standard deviation and non-normally distributed data as median, followed by the interquartile range (IQR; IQ1-IQ3). For comparing categorical variables, Pearson χ 2 test was used. For comparing continuous variables, Student t test was used and Mann-Whitney U test in the case of non-normally distributed data. To make comparisons between FG+ probands and FG+ relatives, generalized linear mixed models were used, with random intercepts for family to account for family relatedness. Survival curves were constructed according to the Kaplan-Meier method. Comparisons of survival and other clinical outcomes between FG+ probands with HCM and FG+ relatives with HCM were performed by using Cox models. To estimate the standard errors of the hazard ratios while taking into account family relatedness, the grouped jackknife method was used. Fisher exact test was used in case of a zero cell count in either of the groups. Log-rank test was used for comparison of survival between FG+ patients and G+ or G− patients. For comparison of consecutive echocardiographic data, the paired t test and in case of non-normally distributed data, the Wilcoxon signed-rank test were used. Statistical significance was defined by P<0.05.
Results
Study Population
In 141 FG+ probands (age, 45±14 years; 66% men), HCM was diagnosed in 134 (95%), NCCM in 4 (3%), and DCM in 3 (2%). In 130 FG+ relatives (age, 42±15 years; 37% men), HCM was diagnosed in 54 (42%), NCCM in 1 (1%), and DCM in 1 (1%). The remaining 74 (57%) were FG+/phenotype-negative (Ph−). Baseline characteristics of the study population are presented in Table 1 .
Genetic Test Results
In FG+ carriers, the c.2373dupG mutation was the most frequent (46%), followed by c.2827C>T (32%) and c.2864_2865delCT (22%). A complex genotype was present in 4 (1%); 3 probands and 1 relative. Complex genotypes were compound heterozygosity for the c.2373dupG and c.2827C>T mutations, homozygosity for the c.2827C>T mutation, compound heterozygosity for the c.2373dupG and c.442G>A (G148R) mutations in the MYBPC3 gene, and a digenic mutation (c.2827C>T in the MYBPC3 gene and c.222dupA; p.Leu75fs in the ankyrin repeat domain 1 gene).
In G+ probands, pathogenic mutations were present in the MYBPC3 gene (45%), ß-myosin heavy chain (29%), cardiac troponin T (7%), cardiac-regulatory myosin light chain (6%), cardiac troponin I (5%), calreticulin 3 (2%), cardiac-essential myosin light chain (2%), andcysteine-and glycine-rich protein 3 (2%), and complex genotypes were present in 3 (2%). Complex genotypes were (1) 
Baseline Clinical and Echocardiographic Characteristics
Main reasons for evaluation in probands were cardiac symptoms (61%), systolic murmur (20%), and abnormal electrocardiography (16%). Five (1%) probands presented with cardiac arrest. All FG+ relatives were evaluated in the context of family screening. Men predominated in all groups. The clinical phenotype of FG+ probands with HCM was similar to G+ probands with 
Echocardiographic Findings During Follow-Up of FG+ Carriers
Echocardiographic findings during 10±6 years of follow-up of FG+ probands and FG+ relatives with HCM are presented in Table 2 . Figure 1 demonstrates the clinical HCM disease stages 18 at baseline and during follow-up of FG+ probands and FG+ relatives. A significant proportion of FG+ probands (29%) progressed to stage III (adverse remodeling) and 18% to stage IV (overt dysfunction); in FG+ relatives, only 5% progressed to stage III and none to stage IV. Systolic dysfunction during follow-up was frequently present in G+ and FG+ HCM (46% versus 46%; log-rank P=0.23) and less frequent in G− HCM than in FG+ HCM (31% versus 46%; log-rank P<0.001). Moderate-to-severe systolic dysfunction was also frequently present in G+ and FG+ HCM (15% versus 25%; log-rank P=0.54) and less frequent in G− HCM than in FG+ HCM (7% versus 25%; log-rank P<0.001).
Mortality and Interventions During Follow-Up
Mortality and interventions are presented in Table 3 . Cardiovascular mortality was 21% in FG+ probands with HCM and 14% in G+ probands (P=0.14), and cardiovascular mortality was significantly lower in FG+ relatives with HCM (4%) and G− probands (7%; Figure 2 
FG+/Ph− Relatives
Characteristics and outcomes of FG+/Ph− relatives versus FG+ HCM are presented in Table 4 . FG+/Ph− relatives were predominantly women (63% versus 35%; P<0.001); there was no significant age difference. During 6±4 years of follow-up, there were no cardiovascular deaths among FG+/Ph− relatives. Echocardiographic follow-up was available in 44 (59%) FG+/ Ph− relatives (Table 5) . After 6±3 years, 5 (11%) FG+/Ph− subjects developed HCM. These 5 subjects were asymptomatic and without LVOT obstruction; conversion occurred at a median age of 37 (range, 25-71) years. Baseline electrocardiographic abnormalities were present in 3 (2 pathological Qs inferior/lateral and 1 nonpathological Q inferior), and anterior mitral valve leaflet elongation ≥30 mm in 1 (20%). Systolic anterior motion and diastolic dysfunction were absent in all 5. Hypertrophy developed at a pace of a median 0.5 (IQR, 0.2-0.8) mm per year during a median 6 (IQR, 3.5-9)-year follow-up, in which MWT increased from a median 11 (IQR, 9.5-11.5) to 13 (IQR, 13-13.5) mm.
Noncompaction and DCM in FG+ Carriers
NCCM was diagnosed in 5 (3%) FG+ carriers; 4 probands and 1 relative. A complex genotype was present in 3 (60%): 2 FG+ probands who experienced HF-related death within 2 months after birth and one 18-year-old asymptomatic FG+ relative. One NCCM patient experienced HF-related death at 50 years of age. DCM was diagnosed in 4 (2%) FG+ carriers; 3 probands and 1 relative. A complex genotype was present in 1 (25%), leading to cardiac transplantation at the age of 8 years. Another FG+ proband with DCM died of HF at 1 year of age. Figure 3 presents cardiac magnetic resonance and echocardiographic imaging, demonstrating the overlap of HCM and NCCM within 1 family and the presence of NCCM in an FG+ carrier.
Discussion
Key findings from the current long-term follow-up study are (1) clinical phenotype and outcome of FG+ HCM was similar to G+ HCM but worse than G− HCM and FG+ HCM diagnosed in the context of family screening and (2) cardiac events (19) 5 (10) 16 (12) 26 (9) ICD 2nd prevention, n (%) 5 (4) 2 (4) 6 (5) 21 We also observed a higher cardiovascular mortality rate in FG+ HCM in comparison with G− HCM. Several studies have previously demonstrated an increased risk of cardiac death in G+ versus G− HCM, [22] [23] [24] including studies of MYBPC3 founder mutations. 25, 26 G− probands in this study were older and more symptomatic most likely related to LVOT obstruction and diastolic dysfunction. Possibly, G− HCM represents a separate disease with a different pathophysiology. Unlike previous observations, 27 we did not observe a lower complication rate in FG+ versus G+ patients.
Initial cardiac screening revealed HCM in 42% of FG+ relatives, which is comparable with previous studies (24%-62%). 26, [28] [29] [30] [31] Extreme hypertrophy was absent in FG+ relatives, and there was less adverse remodeling. Identification of HCM leads to lifestyle modifications, periodic SCD risk stratification, and close clinical follow-up, with the opportunity to implant an ICD for primary prevention and timely referral for septal reduction therapy. In the future, early disease identification might lead to novel therapies to prevent hypertrophy 32 or delay progression to advanced disease stages. 33 In this study, the clinical phenotypes of FG+ carriers showed substantial variation. The clinical heterogeneity in subjects carrying the same pathogenic mutation is intriguing. Basic studies have shown a decrease in the force-generating capacity of cardiomyocytes in G+ HCM patients. 8, 9 For MYBPC3 mutations, the force-generating capacity normalized after correction for myofibril density. 9 The drop in force was Figure 2 . Kaplan-Meier survival analysis for cardiovascular mortality. P indicates the P value calculated with log-rank test in Dutch MYBPC3 founder mutation (FG+) vs genotype-positive (G+) probands (in green) and in FG+ vs genotype-negative (G−) probands (in yellow). In FG+ probands vs FG+ relatives with hypertrophic cardiomyopathy (HCM), the P value (in purple) was calculated with a cox model with grouped jackknife method. In FG+/phenotype-negative (Ph−) relatives, the Cox model with grouped jackknife method did not converge because of insufficient number of events. 9 Other triggers, for example, altered Ca 2+ handling and disturbances in myocardial energetics 34 are additionally being investigated. The exact pathways from mutation to disease remain largely unknown. The relatively large population of FG+ carriers is useful for translational research in which clinical data are combined with data from basic research to further unravel the pathomechanism and identify secondary disease modifiers, such as additional (epi)genetic variations and environmental disease triggers.
FG+/Ph− Individuals
Because of the known age-related penetrance in HCM, 29 longterm follow-up of FG+/Ph− subjects is recommended. 13, 20, 35 The interval at which clinical evaluation should be repeated is subject to debate. The American guideline recommends a 1-to 2-year interval for family members aged 10 to 20 years and 2-to 5-year interval for those >20 years, whereas the European guideline does not advise a specific interval. 13, 20 In this study, 11% of FG+/Ph− relatives developed a subtle form of HCM after 6 years of follow-up. Additionally, comparable with previous studies, 31, 36, 37 the prognosis of FG+/Ph− relatives was good. These findings support cardiac follow-up of adult FG+/ Ph− relatives with a low frequency, as advised by the American guideline. 20 The number of family members aged <18 years in our cohort was too small to propose screening intervals for this group. However, Jensen et al 36 reported a similarly low manifestation rate (6%) in 36 at-risk relatives <18 years of age during 12 years of follow-up. The main advantage of genetic testing in relatives is reassurance in case the mutation is absent. However, the identification of FG+/Ph− subjects currently has limited therapeutic and prognostic consequences because at present, no therapy is available to retard or prevent the development of HCM, 32, 33 and clinical manifestation cannot be predicted. 35 Moreover, a FG+/Ph− status may have psychological and socioeconomic implications. 38 Clearly, cardiogenetic counseling of relatives should include a balanced discussion of the advantages and potential disadvantages of genetic testing.
NCCM and DCM in FG+ Carriers
MYBPC3 mutations are associated with various forms of cardiomyopathies, such as DCM and NCCM. 5 In this study, a significantly poor outcome was observed in a minority of young 39 Because MYBPC3 founder mutations are truncating mutations leading to haploinsufficiency, 8 compound heterozygous or homozygous mutations would theoretically result in human MYBPC3 knockouts (no functional MYBPC3 protein), leading to severe HF at a young age. 39 The likelihood of compound heterozygotes or homozygotes in countries with founder mutations is increased. 5 The finding of NCCM and DCM in the FG+ population and within 1 family supports previous suggestions that the various cardiomyopathies are part of a cardiomyopathy spectrum with similar pathogenesis. Lorca et al 40 similarly described the overlapping of HCM and NCCM phenotypes within 1 family.
Male Predominance in HCM
The male predominance in HCM patients was previously partly explained by a referral bias. 41 In this study, there was also a male predominance in FG+ relatives with HCM eliminating referral bias. Other theories explaining sex differences in HCM include differential gene regulation and the protective effect of estrogens. 41 Another explanation might be the use of the 13-mm cutoff value to diagnose HCM in relatives. 13 In this study, the difference in MWT between male and female relatives disappeared after indexing for body surface area, suggesting that women are clinically underdiagnosed or men over diagnosed. Recommendations for cardiac chamber quantification report different normal ranges for septal and posterior wall thickness in men (6-10 mm) and women (6-9 mm). 42 Therefore, either indexing to body surface area or creating sex-specific cutoff values for family members might lead to a higher diagnostic accuracy.
Limitations
This FG+ population is specific for the Netherlands, and, therefore, it might be difficult to extrapolate these findings to other countries. Follow-up echocardiography was not available in all subjects. Because of developments in genetic testing methodology over time, extended genotyping was not performed in all subjects. Because autopsy was not routinely performed in SCD cases, comorbidities such as coronary artery disease cannot be fully excluded.
Conclusions
Clinical phenotype and outcome of FG+ HCM was similar to G+ HCM but worse than G− HCM and FG+ HCM diagnosed in the context of family screening. These findings indicate the need for more intensive follow-up of FG+ and G+ HCM versus G− HCM and FG+ HCM in relatives.
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